AAV基因增强截短型补体因子H在小鼠模型中差异性挽救眼部补体失调
本研究以Cfh-/-小鼠为补体失调模型,通过视网膜下或尾静脉注射表达截短型CFH(tCFH)或FHL-1的AAV载体,评估其对眼和血浆补体替代途径的恢复效果。结果显示视网膜下注射tCFH可挽救眼内因子B(FB)滞留而FHL-1不能;尾静脉注射后两者均恢复血浆FB检测,但均不能显著调节局部眼部补体。结论提示人CFH的C末端为小鼠眼补体调节所必需,且外源性CFH须局部合成才能最大化视网膜补体调节。
要点
- 视网膜下注射tCFH可挽救Cfh-/-小鼠眼内FB滞留,而FHL-1不能。
- 尾静脉注射后tCFH和FHL-1均恢复血浆FB检测,但均不能显著调节局部眼部补体。
- 人CFH的C末端为小鼠眼补体调节所必需,外源性CFH须局部合成以最大化视网膜补体调节。
核心结论
- 人CFH的C末端为小鼠眼补体调节所必需,外源性CFH须局部合成才能最大化视网膜补体调节。
- 上述发现为开发基于CFH增强的眼部基因治疗奠定关键基础。
研究设计与样本
- 以Cfh-/-小鼠作为补体失调模型,使用表达tCFH或FHL-1的AAV载体经视网膜下或尾静脉注射,评估构建体疗效。
主要发现
- 视网膜下注射后,tCFH表达挽救眼内FB滞留,而FHL-1表达未挽救。
- 尾静脉注射后,tCFH和FHL-1两种构建体均恢复血浆FB检测。
- 肝转导后tCFH和FHL-1蛋白从循环蓄积于后眼杯,但两者均不能显著调节局部眼部补体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Complement dysregulation in the eye has been implicated in the pathogenesis of age-related macular degeneration (AMD), and genetic variants of complement factor H (CFH) are strongly associated with AMD risk. We therefore aimed to untangle the role of CFH and its splice variant, factor H-like 1 (FHL-1), in ocular complement regulation derived from local versus circulating sources. We assessed the therapeutic efficacy of adeno-associated viruses (AAVs) expressing human FHL-1 and a truncated version of CFH (tCFH), which retains the functional N- and C-terminal ends of the CFH protein, in restoring the alternative complement pathway in Cfh-/- mouse eyes and plasma. METHODS: Using Cfh-/- mice as a model of complement dysregulation, AAV vectors expressing tCFH or FHL-1 were injected subretinally or via tail vein, and the efficacy of the constructs was evaluated. RESULTS: Following subretinal injections, tCFH expression rescued factor B (FB) retention in the eye, but FHL-1 expression did not. By contrast, both constructs restored FB detection in plasma following tail vein injections. Both tCFH and FHL-1 proteins accumulated in the posterior eyecup from the circulation following liver transduction; however, neither was able to significantly regulate local ocular complement. CONCLUSIONS: Our findings demonstrate that the C-terminus of human CFH is necessary for complement regulation in the murine eye. Furthermore, exogenous CFH must be synthesized locally to maximize complement regulation in the retina. These findings establish a critical foundation for development of CFH augmentation-based gene therapies for the eye.
引用
- Grigsby D, Klingeborn M, Kelly U, et al. AAV Gene Augmentation of Truncated Complement Factor H Differentially Rescues Ocular Complement Dysregulation in a Mouse Model. Invest Ophthalmol Vis Sci. 2023. PMID: 37471073. doi:10.1167/iovs.64.10.25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。